1. Constantino T. IMS health forecasts global drug spending to increase 30 percent by 2020, to $1.4 trillion, as medicine use gap narrows (https://www.imshealth.com/en/about-us/news/ims-health-forecasts-global-drug-spending-to-increase-30-percent-by-2020). IMS Health Nov 18, 2015.
2. FDA. Orange book: approved drug products with therapeutic equivalence evaluations. 36th ed. pp. vii.
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf2016
.
3. FDA. Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted under an ANDA.
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm377465.pdf2013
.
4. FDA. Guidance for Industry: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. .
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM401695.pdf2014
.
5. FDA. Guidance for Industry: Liposome Drug Products - chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation. .
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070570.pdf2015
.